他汀类药物使用与冠状动脉CT血管成像所示冠状动脉疾病表型及心血管结局之间的交互作用
本研究分析2013年1月1日至2020年12月31日转诊行冠状动脉CTA的11026例连续患者,评估他汀使用年化天数每增加10%与主要不良心脏事件的关系。结果显示他汀使用增加与CAD患者MACE风险降低相关,在阻塞性CAD、高危斑块、钙化积分≥400及节段累及评分>4时更明显,而无CAD患者未见获益。
要点
- 他汀使用每增加10%,CAD患者MACE风险降低(aHR 0.95),无CAD患者无显著获益。
- 阻塞性CAD者他汀使用每增加10%的MACE aHR为0.91,高危斑块者为0.82。
- 钙化积分≥400者aHR为0.93,节段累及评分>4者aHR为0.89,提示病变越重获益越大。
核心结论
- 他汀降低MACE的疗效取决于CAD表型,随病变范围和严重程度增加以及存在高危斑块而增强;无CAD患者他汀治疗对MACE无获益;冠状动脉CTA可能对优化他汀分配、制定个体化治疗决策以预防MACE起关键作用。
研究设计与样本
- 研究为在三级中心连续纳入因评估慢性冠脉综合征而转诊行冠状动脉CTA的患者,共分析11026例(平均年龄58.6±11.9岁,54.7%为男性),CT于2013年1月1日至2020年12月31日完成;主要终点MACE为全因死亡、急性心肌梗死或因不稳定型心绞痛血运重建的复合终点;他汀使用定义为年化他汀治疗天数(根据已配药处方中他汀天数除以随访时间),按随访期间每增加10%分析。
诊断标准与关键数值
- 在CAD患者中,他汀使用每增加10%与MACE风险降低相关(校正HR 0.95,95%CI 0.92-0.99,P=0.006);无CAD患者中无显著相关(aHR 0.95,95%CI 0.84-1.07,P=0.370)。在包含CAD表型的交互分析中,他汀使用每增加10%在阻塞性CAD者降低MACE风险(aHR 0.91,95%CI 0.85-0.97,P=0.006),在高危斑块者降低(aHR 0.82,95%CI 0.68-0.98,P=0.026),在钙化积分≥400者降低(aHR 0.93,95%CI 0.87-0.99,P=0.024),在节段累及评分>4者降低(aHR 0.89,95%CI 0.84-0.95,P<0.001),而在任何CAD者中无显著相关(aHR 0.95,95%CI 0.85-1.07,P=0.411)。
临床应用与阅片要点
- 冠状动脉CTA可用于识别可能从他汀治疗中获益的CAD表型,如阻塞性CAD、高危斑块、钙化积分≥400或节段累及评分>4;无CAD患者他汀治疗对MACE无获益;冠状动脉CTA可能对优化他汀分配、制定个体化治疗决策以预防MACE起关键作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Although statins are recommended for decreasing cardiovascular risk, their efficacy across different patient phenotypes stratified by coronary artery disease (CAD) remains unclear.
OBJECTIVES: This study aims to evaluate whether statins decrease major adverse cardiac events (MACE) among CAD phenotypes according to severity, vulnerability and extent categorized by coronary computed tomography angiography (CTA).
METHODS: The authors analyzed consecutive patients who were referred for coronary CTA at a tertiary center for the assessment of chronic coronary syndrome. The primary endpoint was MACE defined as a composite of all-cause mortality, acute myocardial infarction, or revascularization for unstable angina. Statin use was defined as annualized days on statin therapy (days on statin based on redeemed prescriptions, divided by follow-up time), and analyzed for each 10% increase in statin use over the follow-up period. Interaction analysis, adjusting for risk factors was applied to define treatment benefit across CAD phenotypes.
RESULTS: Overall, 11,026 individuals (mean age: 58.6 ± 11.9 years, 54.7% male) were analyzed who underwent coronary CTA between January 1, 2013, and December 31, 2020. A 10% increase in statin use was associated with lower risk for MACE the stratified Cox-regression model in patients with CAD (adjusted HR [aHR]: 0.95 [95% CI: 0.92-0.99]; P = 0.006), but not in patients without CAD (aHR: 0.95 [95% CI: 0.84-1.07]; P = 0.370). In the total population using interaction analysis including CAD phenotypes, a 10% increase in statin use decreased the risk for MACE in the presence of obstructive CAD (aHR: 0.91 [95% CI: 0.85-0.97]; P = 0.006), high-risk plaque (aHR: 0.82 [95% CI: 0.68-0.98]; P = 0.026), calcium score of ≥400 (aHR: 0.93 [95% CI: 0.87-0.99]; P = 0.024), and segment involvement score of >4 (aHR: 0.89 [95% CI: 0.84-0.95]; P < 0.001), but not for any CAD (aHR: 0.95 [95% CI: 0.85-1.07]; P = 0.411).
CONCLUSIONS: Statin efficacy to decrease MACE depends on CAD phenotypes and increases with the extent and severity of disease and in the presence of high-risk plaques. Patients without CAD have no benefit from statin therapy regarding MACE. Coronary CTA may play a pivotal role in optimizing statin allocation for personalized treatment decisions to prevent MACE.
引用
- Szilveszter B, Vattay B, Boussoussou M, et al. Interaction Between Statin Use, Coronary Artery Disease Phenotypes, on Computed Tomography Angiography, and Cardiovascular Outcomes. JACC Cardiovasc Imaging. 2025. PMID: 40758077. doi:10.1016/j.jcmg.2025.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。